A few hundred yuan, a few hours, you can achieve human genome sequencing, crack all the "secrets" in the gene. This is the future blueprint released by Jinshi Technology Co., LTD. (hereinafter referred to as "Jinshi Technology") at the press conference of the nanopore gene sequencer engineering prototype held on December 24.

It is reported that this is the first engineering prototype of a gene sequencer aimed at a wide range of clinical medical applications in China, with a clear technical route, which is expected to break through the bottleneck that the data quality of the current nanopore sequencer is difficult to meet a wide range of clinical medical needs, and to consolidate the foundation and provide power for precision medicine. Today, science and technology to make gene sequencing become a routine means of precision medicine, improve the level of human health as the vision and mission, or will contribute to changing the long-term monopoly of high-end gene sequencers by foreign countries.

 Gene sequencing becomes routine in precision medicine

At the press conference, the relevant person in charge of the company explained and displayed the principle, system composition, sequencing process and sequencing data of the sequencing machine engineering prototype. According to reports, the prototype can automatically complete the whole process of long read and long sequencing based on the predetermined method of "protein nanopore sequencing while synthesis and sequencing". From the field demonstration, the whole sequencing process does not require any manual operation except adding the samples to be tested, and has a very high degree of automation.

According to the person in charge, the target product corresponding to the prototype is a nanopore gene sequencer with independent intellectual property rights and extremely high design performance parameters. On the basis of the framework of the prototype that has been launched, based on the clear technical route, after subsequent optimization, the design and sequencing accuracy of the instrument will reach more than 99.9999%, and the average read length will exceed 10kbp, which can complete various related detection requirements such as genome, metagenome, transcriptome and methylation. It is expected to become the first nanopore gene sequencer that can be widely used in clinical medicine in China. What benefits will the commercial use of such a sequencer bring to ordinary people? In this regard, the relevant person in charge of the company used the "price of several hundred yuan, a few hours of time, you can complete the human genome sequencing, from prevention, screening, diagnosis, treatment to prognosis of precision medicine to provide accurate data support" to summarize. Specifically, "several hundred yuan" means that after the launch of the target product, the cost of human whole genome sequencing, which currently requires about $1,000, can be greatly reduced to less than 1,000 yuan, which will vigorously promote its wide application in clinical medicine and many other fields, and gradually become a routine diagnosis and treatment method of precision medicine that ordinary people can enjoy. "A few hours" means that with the target product, the whole process from nucleic acid extraction, library construction, sequencing, data analysis to the issuance of reports can be completed in an automated way within 10 hours, which is convenient and fast, and can be applied to a wider range of clinical application scenarios.

The relevant person in charge of the company said: the company has developed a three-step strategic plan for research and development and commercial use, and has completed the first step, that is, the launch of engineering prototypes basically consistent with the final product architecture; Next, the team will continue to work hard to launch the first nanopore sequencer product for the scientific research market in about a year, that is, at the end of 2021, early 2022, and start the medical device marketing license application for NMPA.

On this basis, it will take about two years to launch a 10M throughput high-end sequencer for the clinical market, achieve the project goal of reducing the cost of human whole genome sequencing to less than 1,000 yuan, complete the whole sequencing process within a few hours, obtain the NMPA listing license, and break the monopoly situation of European and American companies on high-end gene sequencers. To become the leader of China''s gene sequencing industry and make due contributions to improving the health level of the whole people.

"This is the full version of the science and technology conference", click the link to watch：https://v.qq.com/x/page/r321502k0ee.html?sf=uri